Li‐Tzong Chen

17.9k citations
297 papers · 7.4k · 3 hit papers · h-index 41

Impact in

  • Hepatology top 0.5%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Gastrointestinal Tumor Research and Treatment

Papers in

    • Pancreatic and Hepatic Oncology Research 65
    • Colorectal Cancer Treatments and Studies 19
    • Cholangiocarcinoma and Gallbladder Cancer Studies 35

Li‐Tzong Chen

287 papers receiving 7.3k citations

Li‐Tzong Chen's Hit Papers

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. 2022 · 164 citations
1640+4+8Years since publication100200300400

Peers

Li‐Tzong Chen
Comparison fields: 5 of 129
  • Hepatology 1.0k
  • Gastroenterology 503
  • Oncology 2.0k
  • Cancer Research 938
  • Pathology and Forensic Medicine 835
Replace Bassel F. El‐Rayes with:
Bassel F. El‐Rayes United States
Scott M. Wilhelm United States
Hans Prenen Belgium
Kun‐Huei Yeh Taiwan
Fritz Wrba Austria
Michelangelo Fiorentino Italy
Marina Talamonti United States
Shoji Nakamori Japan
Tsutomu Fujii Japan
Won Ki Kang South Korea
Li‐Tzong Chen relative to Bassel F. El‐Rayes United States Bassel F. El‐Rayes's profile →
Citations per field
00.5×3.1×
Bassel F. El‐Rayes · 1×
Citations per year

Countries citing papers authored by Li‐Tzong Chen

Since Specialization
Citations

This map shows the geographic impact of Li‐Tzong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li‐Tzong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li‐Tzong Chen more than expected).

Fields of papers citing papers by Li‐Tzong Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li‐Tzong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li‐Tzong Chen. The network helps show where Li‐Tzong Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Li‐Tzong Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Li‐Tzong Chen Line = papers co-authored together Li‐Tzong Chen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 297 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Hit paper breakdown →
2014450
2
Management of gastric cancer in Asia: resource-stratified guidelines
Hit paper breakdown →
2013385
3 2009326
4 2019212
5 2004183
6
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
Hit paper breakdown →
2022164
7 2016153
8 2013134
9 2005128
10 2013120
11 2010117
12 2011110
13 201898
14 201295
15 200481
16 201777
17 201774
18 201571
19 200469
20 201369

About Li‐Tzong Chen

Li‐Tzong Chen is a scholar working on Oncology, Surgery, Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 297 papers that have together received 7.4k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (65 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers), Gastric Cancer Management and Outcomes (31 papers), Gastrointestinal Tumor Research and Treatment (20 papers), Colorectal Cancer Treatments and Studies (19 papers), Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Neuroendocrine Tumor Research Advances (19 papers) and Lymphoma Diagnosis and Treatment (17 papers). The work is most often cited by research in Hepatology (1.0k citations), Gastroenterology (503 citations), Oncology (2.0k citations), Cancer Research (938 citations) and Pathology and Forensic Medicine (835 citations). Li‐Tzong Chen has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include Yan‐Shen Shan, Ann‐Lii Cheng, Jeffrey S. Chang, Jang‐Yang Chang, Yoon‐Koo Kang, Kun‐Huei Yeh, Wen‐Chun Hung, Nai‐Jung Chiang, Chiun Hsu and Chien‐Feng Li. Their work appears in journals such as Journal of Clinical Oncology, Oncotarget, Scientific Reports, Cancers and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact